New updates have been reported about SandboxAQ (SANDB)
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SandboxAQ has announced significant contributions to OpenFold3, an open-source biomolecular co-folding model developed by the OpenFold Consortium. This model is set to revolutionize drug discovery by accurately predicting protein-molecule structures, a crucial capability for commercial drug development. Leveraging its expertise in AI model building and computational chemistry, SandboxAQ has helped enhance the infrastructure and capabilities of OpenFold3, positioning it as the most extensively trained public co-folding model available. This advancement is expected to seed a new ecosystem of AI-driven drug discovery tools, with SandboxAQ planning to release several capabilities in the coming months.
The innovations introduced by SandboxAQ are part of its broader portfolio of Large Quantitative Models (LQMs), which are based on fundamental mathematical principles rather than existing literature. These models allow for extensive exploration of chemical space and rapid optimization of drug portfolios, significantly reducing the time required for drug development. According to Adam Lewis, Head of Innovation at SandboxAQ, the company’s contributions to OpenFold3 will empower researchers to tackle challenging medical conditions such as cancer and neurodegenerative diseases with advanced technologies and data. The OpenFold3 model is accessible through various platforms, including Github and HuggingFace, and is supported by partners like Tamarind Bio and Apheris. SandboxAQ, originally part of Alphabet Inc., continues to drive innovation at the intersection of AI and quantum techniques, supported by leading investors and strategic partners.